Journal article icon

Journal article

VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy.

Abstract:

Bevacizumab, an anti-vascular endothelial growth factor (VEGF-A) antibody, is used in metastatic colorectal carcinoma (CRC) treatment, but responses are unpredictable. Vascular endothelial growth factor is alternatively spliced to form proangiogenic VEGF(165) and antiangiogenic VEGF(165)b. Using isoform-specific enzyme-linked immunosorbent assay and quantitative polymerase chain reaction, we found that over 90% of the VEGF in normal colonic tissue was VEGF(xxx)b, but there was a variable upre...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1038/sj.bjc.6604308

Authors


Rennel, ES More by this author
Perrin, RM More by this author
Expand authors...
Journal:
British journal of cancer
Volume:
98
Issue:
8
Pages:
1366-1379
Publication date:
2008-04-05
DOI:
EISSN:
1532-1827
ISSN:
0007-0920
URN:
uuid:261f4330-6923-4162-95f1-ae1909ee95d1
Source identifiers:
246750
Local pid:
pubs:246750

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP